Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jul;136(1):120-127.
doi: 10.1111/bju.16720. Epub 2025 Apr 4.

The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy

Kai Zhang  1 , Jeremy Teoh  2 , Pilar Laguna  3 , Jose Dominguez-Escrig  4 , Eric Barret  5 , Juan Casanova Ramon-Borja  4 , Gordon Muir  6 , Julia Bohr  7 , Paula Pelechano Gomez  8 , Theo M de Reijke  9 , Chi-Fai Ng  2 , Chi-Ho Leung  2 , Rafael Sanchez-Salas  10 , Jean de la Rosette  11
Affiliations
Randomized Controlled Trial

The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy

Kai Zhang et al. BJU Int. 2025 Jul.

Abstract

Objective: To investigate the diagnostic value of magnetic resonance imaging (MRI) for persistent prostate cancer after irreversible electroporation (IRE) therapy.

Patients and methods: This is a post hoc analysis from a multicentre randomised trial, in which men with localised low- to intermediate-risk prostate cancer were randomised to receive either focal or extended IRE ablation. All patients underwent repeat MRI scans at 6 and 12 months and transperineal template mapping biopsy (TMB) at 6 months post-IRE. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MRI were calculated for infield and outfield lesions using 2 × 2 contingency tables with 95% confidence intervals (CIs) for clinically significant prostate cancer and any-grade prostate cancer.

Results: A total of 106 patients were recruited to this study, including 39 patients (37%) with clinically insignificant prostate cancer and 67 patients (63%) with clinically significant prostate cancer (International Society of Urological Pathology grade ≥2). Of these, 101 patients underwent repeat MRI scan and prostate biopsy at 6 months after IRE. The rate of clinically significant prostate cancer detected by TMB infield and outfield was 9.9% (10/101) and 9.9% (10/101), respectively. In the treated area, the sensitivity, specificity, PPV and NPV for MRI to detect clinically significant prostate cancer were 30% (95% CI 6.7%-65%), 91% (95% CI 82%-96%), 27% (95% CI 6.0%-61%) and 92% (95% CI 84%-97%), respectively. In the untreated area, the sensitivity, specificity, PPV and NPV of MRI to detect clinically significant prostate cancer were 20% (95% CI 2.5%-56%), 91% (95% CI 82%-96%), 20% (95% CI 2.5%-56%) and 91% (95% CI 82%-96%), respectively.

Conclusion: Favourable specificity but poor sensitivity was achieved with use of MRI to detect persistent clinically significant prostate cancer after IRE treatment. Repeat TMB should not be deferred, regardless of MRI results.

Keywords: MRI; diagnosis; focal therapy; irreversible electroporation; residual prostate cancer.

PubMed Disclaimer

References

    1. Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Fütterer JJ, Rovers MM. An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 2022; 81: 5–33
    1. Valerio M, Cerantola Y, Eggener SE et al. New and established Technology in Focal Ablation of the prostate: a systematic review. Eur Urol 2017; 71: 17–34
    1. Zhang K, Teoh J, Laguna P et al. Effect of focal vs extended irreversible electroporation for the ablation of localized low‐ or intermediate‐risk prostate cancer on early oncological control: a randomized clinical trial. JAMA Surg 2023; 158: 343–349
    1. Reddy D, Peters M, Shah TT et al. Cancer control outcomes following focal therapy using high‐intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi‐institute 15‐year experience. Eur Urol 2022; 81: 407–413
    1. Shah TT, Reddy D, Peters M et al. Focal therapy compared to radical prostatectomy for non‐metastatic prostate cancer: a propensity score‐matched study. Prostate Cancer Prostatic Dis 2021; 24: 567–574

Publication types

LinkOut - more resources